MedTrace Logo

Curing Atrial Fibrillation in Heart Failure

NCT00292162 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2012-06-01

Study results available
· View outcomes & findings →

Summary

Heart failure is a condition that occurs when the heart muscle weakens and no longer contracts normally. Half of these patients have an irregularity of heart rhythm called atrial fibrillation (AF). Patients with both heart failure and AF spend more time in hospital, and die earlier than those with heart failure alone. AF is difficult to treat with conventional methods in patients with heart failure. Radiofrequency ablation is a new technique used to cure AF. The investigators aim to establish if radiofrequency ablation for atrial fibrillation in patients with advanced heart failure can result in marked improvement in the function of the heart.

Conditions

Interventions

PROCEDURE

radiofrequency ablation

isolation of the pulmonary veins with radiofrequency ablation (RFA)

DRUG

ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril

Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.

DRUG

Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol

Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.

DRUG

Aldosterone Antagonists - spironolactone

Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Derek T Connelly, MBChB · Glasgow Royal Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292162 on ClinicalTrials.gov